Drug Profile
Research programme: Mullerian Inhibiting Substance therapeutics - Chlorogen
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Chlorogen
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 30 Jul 2007 Preclinical development is ongoing
- 30 Jul 2007 Mullerian Inhibiting Substance therapeutics are available for licensing worldwide (http://www.chlorogen.com)